This was a month that will likely be remembered as when Takeda and Shire shook hands on a $62 billion deal for the Japanese drugmaker to take over the rare diseases specialist.
If the deal goes through — and there are still a few obstacles to be overcome Takeda shareholders will own around 50% of the combined group.
There were also a couple of other acquisitions worth more than $1 billion, with two big pharma players adding to their assets in the immuno-oncology space and a merger creating the leading player in the Australian generics market.
The table below details the deals announced.
|Janssen||BeneVir||$1.04 billion||To add BeneVir’s oncolytic immunotherapy platform to Janssen’s immuno-oncology efforts|
|Takeda||Shire||$62 billion||To create a combined group that is a global, values-based, R&D-driven biopharmaceutical leader — provided the deal goes through|
|Strides Arcolab (Arrow)||Apotex||Share swap giving Strides the controlling interest||To create the leading player in the Australian generics market|
|Eli Lilly||ARMO BioSciences||$1.6 billion||To bolster Lilly’s immuno-oncology program|
|TapImmune||Marker Therapeutics||A merger-of-equals under which the stockholders of TapImmune and Marker will each own around 50% of the combined company||To add to TapImmune’s pipeline a synergistic portfolio of highly-differentiated T-cell therapies that has demonstrated impressive results in early trials|
|Fujifilm Holdings||Remaining stake in Toyama Chemical||Reportedly $549 million to $640 million||To strengthen Fujifilm’s health care arm, offering an alternative revenue stream to the struggling mainstay office equipment business|
|Shanghai Pharmaceutical Holding and a fund managed by SFund International Investment Fund Management||Takeda’s 51.34% stake in Guangdong Techpool Bio-Pharma||Approximately $280 million||A divestment to allow Takeda greater focus on its key areas of focus|
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Date: June 06, 2018